Membranous glomerulonephritis pathophysiology

Revision as of 12:28, 20 May 2018 by Medhat (talk | contribs)
Jump to navigation Jump to search

Membranous glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranous glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

Ultrasound

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranous glomerulonephritis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranous glomerulonephritis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranous glomerulonephritis pathophysiology

CDC on Membranous glomerulonephritis pathophysiology

Membranous glomerulonephritis pathophysiology in the news

Blogs on Membranous glomerulonephritis pathophysiology

Directions to Hospitals Treating Membranous glomerulonephritis

Risk calculators and risk factors for Membranous glomerulonephritis pathophysiology

Overview

It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].

Pathophysiology

  • MGN is caused by immune complex formation in the glomerulus. The immune complexes are formed by binding of antibodies to antigens in the glomerular basement membrane. The antigens may be part of the basement membrane, or deposited from elsewhere by the systemic circulation.
  • The immune complex serves as an activator that triggers a response from the complement system and form a membrane attack complex which stimulates release of proteases and oxidants by the mesangial and epithelial cells, damaging the capillary walls and causing them to become "leaky".

Phospholipase A2 receptor

  • The M-type PLA2R is the major antigen in human idiopathic MN. It is expressed in glomerular podocytes.
  • There was no colocalization of PLA2R in secondary MN biopsies.
  • PLA2R antigen detected within immune deposits by immunofluorescence of the biopsy specimen. [26]
  • Detection of the immune complex specificity is 100 percent.

Thrombospondin type-1

  • THSD7A has been found in patients with idiopathic MN who are negative for anti-PLA2R antibodies.

Neutral endopeptidase

  • Anti-neutral endopeptidase antibodies caused MN in the neonates.
  • It resolves months after birth.
  • The T helper-2 predominates in MN and minimal change disease.

Genetics

Associated Conditions

Gross Pathology

Microscopic Pathology

  • Early biopsies may be normal
  • Later: uniform diffuse capillary wall thickening without hypercellularity, without mesangial sclerosis and without inflammatory cells
  • Proximal convoluted tubules contain hyaline droplets, reflecting protein reabsorption
  • With progression, get membrane thickening, narrow capillary lumina, mesangial sclerosis and glomerulosclerosis

Immunofluorescence

  • Granular diffuse peripheral deposits, usually IgG and C3, also C5b-C9 and occasionally IgM or IgA
  • C4d immunostaining may be diagnostic (Histol Histopathol 2011;26:1391) 

Stages

  • Stage I: LM - normal for slightly thickened BM, slight GMB vacuolization; IF - fine granular IgG, C3; EM - scattered small subepithelial electron dense deposits, no foot process effacement or spikes
  • Stage II: LM - moderately thickened BM with spikes and vacuolization; IF - moderate sized, granular IgG, C3; EM - diffuse spikes due to subepithelial deposits, diffuse foot process effacement
  • Stage III: LM - markedly thickened GBM, residual spikes and vacuoles, chain like appearance; IF - coarsely granular IgG, C3; EM - intramembranous deposits, spikes, neomembrane formation and diffuse foot process effacement
  • Stage IV: LM - markedly thickened GBM, few spikes, vacuoles and glomerulosclerosis; IF - focal IgG, C3; EM - sclerotic GBM, few deposits and lacunae

Electron microscopy

  • Subepithelial deposits that nestle against the glomerular basement membrane seems to be the cause of the thickening.
  • The podocytes lose their foot processes.
  • As the disease progresses, the deposits will eventually be cleared, leaving cavities in the basement membrane.

References

Template:WH Template:WS

References

Template:WH Template:WS